

## POST-TEST

### *Cases from the Community: Clinical Investigators Provide Their Perspectives on Actual Breast Cancer Cases and the Implications of Emerging Research*

#### THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- Among patients with BC and bulky axillary lymph node metastases who undergo lumpectomy or mastectomy, radiation therapy has been shown to result in an improvement in locoregional control.
  - True
  - False
- In the Phase III CREATE-X trial, the addition of adjuvant capecitabine after standard neoadjuvant chemotherapy elicited the greatest benefit among patients with \_\_\_\_\_ BC and residual invasive disease.
  - ER-positive, HER2-negative
  - Triple-negative
  - HER2-positive
- In the CLEOPATRA study evaluating the addition of pertuzumab to docetaxel/trastuzumab for previously untreated HER2-positive metastatic BC, pertuzumab and trastuzumab were administered for 6 cycles with docetaxel and then \_\_\_\_\_.
  - Trastuzumab was continued until disease progression
  - Trastuzumab and pertuzumab were continued until disease progression
- In the CLEOPATRA study, which of the following was observed with the addition of pertuzumab to docetaxel/trastuzumab?
  - No improvement in overall survival
  - No improvement in overall survival but significant improvement in progression-free survival
  - An approximately 16-month improvement in overall survival
- Despite the absence of evidence for benefit with perioperative aromatase inhibition in the overall population of patients with ER-positive early BC, the POETIC trial did demonstrate low versus high Ki-67 levels to be an independent, significant indicator of good versus poor prognosis.
  - True
  - False
- Which of the following categories reflects the mechanism of action of neratinib?
  - Antibody-drug conjugate
  - Anti-PD-1/PD-L1 antibody
  - HER2-blocking tyrosine kinase inhibitor
- The Phase III BIG 1-98 trial comparing letrozole versus tamoxifen as adjuvant endocrine therapy for postmenopausal women with HR-positive early BC demonstrates that even in patients with luminal A indolent lobular disease, the efficacy of tamoxifen is \_\_\_\_\_ to letrozole.
  - Equivalent
  - Inferior
  - Superior
- The Phase III NCIC CTG MA.27 trial evaluating exemestane versus anastrozole for postmenopausal women with HR-positive early BC demonstrated no difference in efficacy between the 2 arms in the overall patient population.
  - True
  - False
- Results from the Phase III NSABP-B-52 trial evaluating pathologic complete response rates for patients with HR-positive, HER2-positive BC treated with neoadjuvant docetaxel, carboplatin, trastuzumab and pertuzumab with or without estrogen deprivation demonstrated \_\_\_\_\_ in pathologic complete response rates for patients who received estrogen deprivation.
  - No difference
  - A significant increase
- In the Phase III APHINITY trial, the addition of pertuzumab to trastuzumab and chemotherapy significantly improved invasive disease-free survival for patients with HER2-positive early BC.
  - True
  - False